By Shreyashi Sanyal and Sinéad Carew (Reuters) - U.S. stock indexes closed higher on Tuesday with the biggest boosts from the technology and healthcare sectors as investors appeared to bet...
Investing.com – U.S. equities were higher at the close on Tuesday, as gains in the Healthcare, Utilities and Oil & Gas sectors propelled shares higher. At the close in NYSE, the Dow Jones...
By Dhirendra Tripathi Investing.com – Shares of vaccine-makers traded higher Tuesday on a report in The New York Times that the Food and Drug Administration plans to allow people to...
By Geoffrey Smith Investing.com -- The dollar weakens as poor U.S. industrial production data cast fresh doubt on the strength of the U.S. economic recovery. Allegations of insider trading...
Johnson & Johnson (JNJ): Q3 Non-GAAP EPS of $2.60 beats by $0.25; GAAP EPS of $1.37 misses by $0.80.Revenue of $23.34B (+10.7% Y/Y) misses by $380M.Shares +0.4% PM.Press...
By Oliver Gray Investing.com - U.S. stock futures moved slightly lower during early APAC deals on Tuesday, following a mixed session as investors digested strong earnings reports from major...
By Devik Jain, Shreyashi Sanyal and Sinéad Carew (Reuters) - The S&P and Nasdaq closed higher on Monday with the biggest boosts from the highest-profile technology and communications...
Johnson & Johnson (NYSE:JNJ) is scheduled to announce Q3 earnings results on Tuesday, October 19th, before market open.The consensus EPS Estimate is $2.35 (+6.8% Y/Y) and the...
Chinese growth and corporate earnings in the United States and Europe, including results from the big-hitting FAANGs, will give markets plenty to digest in the week ahead, while Turkey's...
By Oliver Gray Investing.com - U.S. stock futures were slightly lower in early APAC deals on Monday, following strong gains in the previous week as market participants cheered a stronger...
By Noreen Burke Investing.com -- The first big wave of earnings reports will give investors plenty to digest in the coming week, while U.S data could help cement expectations for the Federal...
Johnson & Johnson is set to release its Q3 2021 earnings results before the bell on Tuesday.
Johnson & Johnson has about $25 billion of cash and a $10 billion line of credit -- easily enough to set up the proposed victims’ trust fund.
Johnson & Johnson’s Covid vaccine booster gained a key recommendation from advisers to U.S. regulators that brings the additional shot a step closer to clearance.
A panel of outside doctors and experts voted 19-0 to recommend that all adults who received a first dose of the J&J vaccine should get the second dose at least two months later.
FDA committee says it is safe for adults who got J&J vaccine to get a booster
An advisory panel of the FDA has unanimously voted to endorse the COVID-19 vaccine developed by Johnson & Johnson (JNJ).FDA’s Vaccines and Related Biological Products Advisory...
The Food and Drug Administration should authorize a second 'booster' dose of Johnson & Johnson's COVID-19 vaccine for adults who were initially immunized with this vaccine, according to a...
Coronavirus Update: FDA advisory panel set to vote on J&J vaccine booster
Chinese growth and corporate earnings in the United States and Europe, including results from the big-hitting FAANGs, will give markets plenty to digest in the week ahead, while Turkey's...
By Geoffrey Smith Investing.com -- Retail sales and the Michigan Consumer Sentiment index round off a busy week for economic data. Stocks and oil march higher as inflation fears take a back...
Johnson & Johnson (JNJ) announces that LTL Management LLC, a newly created and separate subsidiary, established to hold and manage claims in the cosmetic talc litigation, has filed...
Johnson & Johnson placed into bankruptcy its liabilities for tens of thousands of claims linking talc-based products to cancer, hoping to drive a settlement of personal-injury claims that...
Johnson & Johnson placed into bankruptcy its liabilities for tens of thousands of claims linking talc-based products to cancer, hoping to drive a settlement of personal-injury claims that...
The FDA has granted orphan drug status to Johnson & Johnson's nipocalimab for chronic inflammatory demyelinating polyneuropathy.
A judge set aside more than 15,700 votes backing the personal-injury compensation plan of defunct supplier Imerys Talc America.
By Dhirendra Tripathi Investing.com – Johnson & Johnson stock (NYSE:JNJ) rose by 0.5% in Wednesday’s trading as the Food and Drug Administration said the company’s...
Those who were immunized with the Johnson & Johnson (JNJ) COVID-19 vaccine build a stronger neutralizing antibody response if they received an mRNA shot instead of a second...
A booster dose of Johnson & Johnson's COVID-19 vaccine significant increases protection against symptomatic and severe /critical COVID-19, the company says in briefing documents.
Dr. Paul Stoffels, the executive running Johnson & Johnson's COVID-19 vaccine program, announced he will retire at the end of the year, the company said Tuesday. As J&J's chief scientific...
Johnson & Johnson (JNJ) announced that Dr. Paul Stoffels its chief scientific officer and currently the vice chairman of the executive committee will retire from the company...
Paul Stoffels is the second top J&J executive in recent weeks to announce plans to leave.
The FDA's vaccine advisory committee meeting come less than a month after U.S. regulators authorized third Covid shots of Pfizer's vaccine.
The European Medicines Agency ((EMA)) has approved a U.S
Johnson & Johnson has submitted an sNDA to the FDA seeking approval of Stelara in children 5 years and older for pediatric psoriatric arthritis.
By Yasin Ebrahim Investing.com – The S&P 500 rebounded Tuesday on dip-buying in big tech following a rout a day earlier. The S&P 500 gained 1.4%, the Dow Jones Industrial Average added 1.3%...
By Dhirendra Tripathi Investing.com – Johnson & Johnson stock (NYSE:JNJ) rose 0.7% Tuesday as the company applied to the U.S. Food and Drug Administration for emergency use approval to...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
